This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Kissei Pharmaceutical Co., Ltd

Drug Names(s): KRP-EPA605

Description: KEA-0447 (KRP-EPA605) is a selective prostaglandin E receptor 1 (EP1) antagonist found to suppress detrusor overactivity in the bladder.

Deal Structure: Kissei and KYORIN
In 2009, Kissei and KYORIN reported to have entered into a joint research agreement on the new treatment of overactive bladder.

In 2012, Kissei and Kyorin entered into a joint development agreement in 2012, and with the prospect of initiating a Phase I clinical trial of KEA-0447/KRP-EPA605 for the treatment of overactive bladder.

Partners: Kyorin Pharmaceutical Co., Ltd.

KEA-0447 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug